In contrast to earlier reports, MSI CRC cell lines were not more sensitive to niraparib than MSS CRC cell lines ̧ suggesting that the MSI phenotype does not sensitize CRC cell lines to PARP inhibition. The gene discussed is PARP1; the disease is colorectal carcinoma.